Addition of ipratropium to nebulized albuterol in children with acute asthma presenting to a pediatric office.
A prospective, randomized, double-blind study was conducted to determine whether there was any benefit to the addition of ipratropium to a single nebulized albuterol treatment in infants and children with mild to moderate acute asthma presenting to a pediatric office. There were no significant differences between the albuterol group and the combined albuterol-ipratropium group in the relief of the respiratory distress, disposition of the patients from the office, or in the incidence of relapse. The addition of ipratropium to nebulized albuterol is of no added benefit in the treatment of infants and children with mild-to-moderate acute asthma presenting to a pediatric office.
Kumaratne
Mohan
M
College of Business and Economics, California State University, Fullerton, CA, USA.
Gunawardane
Gamini
G
D000208:Acute Disease; D000280:Administration, Inhalation; D000367:Age Factors; D000420:Albuterol / Q000008:administration & dosage* / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D009241:Ipratropium / Q000008:administration & dosage* / Q000627:therapeutic use*; D008297:Male; D009330:Nebulizers and Vaporizers; D009819:Office Visits; D017063:Outcome Assessment, Health Care; D010372:Pediatrics; D011446:Prospective Studies; D012720:Severity of Illness Index
D001993:Bronchodilator Agents; D009241:Ipratropium; D000420:Albuterol